Pharmaceutical Contract Manufacturing Market: Growth, Size, Share, and Trends

Report Code PH 7263
Published in Aug, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029

Overview

The global pharmaceutical contract manufacturing market growth forecasted to transform from USD 200.9 billion in 2024 to USD 319.6 billion by 2029, driven by a CAGR of 9.7%. Increasing use of generic drugs and funding, developments in the field of CMOs technology, the high cost of in-house drug discovery, and regulatory filing by the CMOs drive the growth of the pharmaceutical contract manufacturing market. Pharma CMOs using Al in drug development and manufacturing will bring efficiency and quality. In April 2024, Lonza launched its AI-powered Route Scouting Service: This service integrates Lonza's global expertise in the chemical supply chain with Elsevier Al technology (Reaxys) for the fast-tracking of artificial route identification for new APIs. Strict rules may limit the growth of the market. Moreover, applies AI in predictive analytics for supply chain management, planning efficient production schedules, and inventory levels. AI also optimizes clinical trials through incidental candidate identification, predictions of clinical trial results, and patient compliance monitoring4 which will lower the costs and raise success rates of clinical trials. It paves the way for further innovations and developments, as bringing Al to pharmaceutical contract manufacturing transforms the whole industry in terms of efficiency, guarantees the quality, and accelerates development processes.

Attractive Opportunities in the Pharmaceutical Contract Manufacturing Market

Asia Pacific

The growth of the Asia Pacific pharmaceutical contract manufacturing market can be attributed to the presence of a large and growing patient population, increasing demand for innovative therapies, and the emergence of small and mid-sized pharmaceutical companies in the region.

Growth in this market is primarily driven by the increasing drug R&D pipeline, technological advancements by CDMOs, and the high cost of in-house drug development.

Globally, North America is the largest market for pharmaceutical contract manufacturing services and this trend is expected to continue during the forecast period.

The need for highly advanced facilities for developing complex cell and gene therapies and the emergence of hybrid models with CRO-CDMO partnerships are key opportunity areas for players in this market.

The Asia Pacific market is estimated to grow at the highest CAGR (14.2%) during the forecast period.

Global Pharmaceutical Contract Manufacturing Market Dynamics

DRIVER: Expensive In-House drug development

Drug research and development is very expensive and long for a small and medium size pharmaceutical company. Pharmaceutical companies find another cost effective and efficient way to outsource their drug development activities to the contract development and research organisations. Furthermore, medication development requires compliance rigorous FDA criteria, and maintaining standards of quality regarding formulation development. This, in turn, adds to the internal cost of expenses on research and production of the therapeutic formulation. As a result of the rise in costs incurred in developing drugs, including discovery and pre-clinical development, clinical development, capital, and the limited funding with high rates faced with the failure of drugs in human trials, the pharmaceuticals have sought to outsource their drug development processes to contract development and manufacturing organizations.

RESTRAINT: Varying regulatory requirements across regions

The failure of the respective authority to adhere to standards and regulations, as well as the production of substandard pharmaceuticals, have significant repercussions for the business and its brand reputation. Therefore, adherence to regulatory rules is of utmost importance in the pharmaceutical industry. CDMOs sell the drug substance/formulation that they manufacture on a contract basis under their own brand. The medication development and clinical trial process necessitates the submission of substantial quantities of data to the regulatory body. Therefore, the management of the data and the submission of diverse formulations in different countries provide challenges for COMOS and heighten the likelihood of errors in regulatory filings. This aspect is expected to impede the market expansion of pharmaceutical Contract Development and Manufacturing Organizations (CDMOs) in the foreseeable future.

 

OPPORTUNITY: Emerging Markets

Emerging countries offer a trained labor and cost advantages, hence they become hubs of bioprocess outsourcing. Furthermore, the increasing interest of pharmaceutical companies in outsourcing medications discovery is ascribed to the growing need for vaccines, declining availability of antibiotics, and rising research and development costs fueling the increase of pharmaceutical contract development and manufacturing activities in developing countries. Moreover, the use of contemporary manufacturing technology and the availability of low-cost manufacturing and labor in underdeveloped nations are motivating market players to invest in Asia Pacific over the expected horizon. Given their growth as growing economies, India and China are expected to present significant opportunities for the near future expansion of the pharmaceutical contract manufacturing and development market based on their features. Furthermore, Biosecure Act seeks to limit technology transfer and reduce the reliance on China for biopharmaceuticals. It basically forbids US federal government agencies from purchasing goods or services from Chinese drug businesses. Under this Act, growing nations like India would have great chances in the pharmaceutical industry. As production moves from China to India against present trends, India's contract manufacturing sector will expand dramatically in the next three years. The segment of contract research in India will also grow noticeably during the same time. US companies are already posing more questions to Indian pharmaceutical companies. Though there is a chance that nations like Ireland or maybe Singapore could possibly present some fierce competition, the Act has no short-term financial advantage due of the common contracts with China. All things considered, the Act speeds India's expansion in the pharmaceutical industry, therefore strengthening its role as one of the main participants in contract manufacturing and research markets.

CHALLENGE: Introduction of Serialization

Serialization—that is, coding every service or product item—allows each one to have a distinct identity. The special identity helps to trace and follow the feet around the supply chain. For companies all around and regulatory authorities, counterfeiting is a major problem. For contract manufacturing, CDMOs all over need a practical pharmaceutical serialization solution. Software, hardware, training, implementation, manufacturing lines—all of which the pharmaceutical sector must make a major capital investment in—all of which need for software handling competent employees spread over multiple locations. This is challenging for a COMO as well. One of the more challenging tasks the pharmaceutical contract research and manufacturing company has ahead of it.

Global Pharmaceutical Contract Manufacturing Market Ecosystem Analysis

The pharmaceutical contract manufacturing market ecosystem comprises pharmaceutical contract manufacturing service providers, big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, academic institutes, CROs, and others.

 

The pharmaceutical manufacturing services segment dominated pharmaceutical contract manufacturing industry in 2023.

Based on service the pharmaceutical contract manufacturing market is segmented into drug development services, pharmaceutical manufacturing services, biologics manufacturing services, packaging & labelling services, fill-finish services, and other services. Rising demand for biologics and biosimilars in the region and variables such the growing biopharmaceuticals and pharmaceutical markets worldwide help to attain the dominating share that pharmaceutical manufacturing services account for in 2023. Moreover, important participants in the market are funding drug development, which would probably help the growth of segment.

The big pharmaceutical companies segment of the pharmaceutical contract manufacturing industry is expected to grow at the highest CAGR during the forecast period.

Based on end user, the pharmaceutical contract manufacturing market is segmented into big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). Over the projected period, the big pharmaceutical companies segment is expected to show the highest CAGR. Rising demand for targeted medication therapies, more biologics now under pipeline research, and more investment in the development of cell and gene therapies are responsible for this significant growth of the segment.

North America region holds the largest share of the Pharmaceutical Contract Manufacturing Market.

The global pharmaceutical contract manufacturing market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. North America was the largest segment in 2023 in the pharmaceutical contract manufacturing market, followed by Europe and the Asia Pacific. Factors such as the presence of a large number of pharmaceutical companies and the growing demand for generics, increased research funding for pharmaceutical contract manufacturing and thus supporting the pharmaceutical contract manufacturing growth.

 
 

Recent Developments of Pharmaceutical Contract Manufacturing Market industry

  • In May 2024, Siren Biotechnology and Catalent, Inc. entered in partnership for manufacturing of AAV Gene Therapies for cancer.
  • In March 2024, Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash.

Key Market Players

KEY PLAYERS IN THE Pharmaceutical Contract Manufacturing Market INCLUDE

Want to explore hidden markets that can drive new revenue in Pharmaceutical Contract Manufacturing Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $200.9 billion
Projected Revenue by 2029 $319.6 billion
Revenue Rate Poised to Grow at a CAGR of 9.7%
Market Driver Expensive In-House drug development
Market Opportunity Emerging Markets

 

Key Questions Addressed by the Report

What is the projected growth rate of the global pharmaceutical contract manufacturing market between 2024 and 2029?
The global pharmaceutical contract manufacturing market is projected to grow from USD 200.9 billion in 2024 to USD 319.6 billion in 2029, demonstrating a robust CAGR of 9.7%.
What are the key drivers of the pharmaceutical contract manufacturing market?
Key drivers include the high cost of in-house drug development, the need for compliance with stringent FDA criteria, and the increasing trend of outsourcing drug development activities to contract development and manufacturing organizations (CDMOs).
What are the main challenges facing the pharmaceutical contract manufacturing market?
The main challenges include varying regulatory requirements across regions, the complexity of managing regulatory filings, and the significant investment required for serialization solutions to combat counterfeiting in the supply chain.
Which regions are expected to experience significant growth in the pharmaceutical contract manufacturing market?
Emerging markets, especially in Asia-Pacific countries like India and China, are expected to see significant growth due to their cost advantages, skilled labor, and increasing interest in outsourcing drug development.
What role does AI play in the pharmaceutical contract manufacturing market?
AI is transforming pharmaceutical contract manufacturing by improving efficiency and quality through predictive analytics, optimizing supply chain management, and fast-tracking route identification for new APIs. AI also plays a role in optimizing clinical trials, improving success rates, and reducing costs.
What are the opportunities for growth in the pharmaceutical contract manufacturing market?
The emerging markets, particularly in Asia-Pacific, offer significant growth opportunities due to lower manufacturing and labor costs, increasing investments in bioprocessing, and the shifting of manufacturing activities from China to countries like India, driven by the Biosecure Act.
What is the impact of regulatory requirements on the pharmaceutical contract manufacturing market?
Varying regulatory requirements across different regions create challenges for CDMOs, especially when managing data submissions for diverse formulations. Adherence to regulations is critical to maintaining quality standards, which can be a major barrier to market expansion.
How is the rise in biologics impacting the pharmaceutical contract manufacturing market?
The increasing demand for biologics and biosimilars is driving the pharmaceutical manufacturing services segment of the market. Many major pharmaceutical companies are investing heavily in biologics API and FDF manufacturing services, supporting the growth of this market segment.
What are the recent developments in the pharmaceutical contract manufacturing market?
Recent developments include Lonza's launch of its AI-powered Route Scouting Service and the acquisition of Genentech's manufacturing facility in Vacaville by Lonza for USD 1.2 billion, as well as the partnership between Siren Biotechnology and Catalent, Inc. for manufacturing AAV gene therapies.
Which companies are the key players in the pharmaceutical contract manufacturing market?
Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific (US), Lonza Group (Switzerland), WuXi Apptec (China), WuXi Biologics (China), AbbVie, Inc. (US), Catalent, Inc. (US), and Samsung Biologics (South Korea).

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
32
RESEARCH METHODOLOGY
37
EXECUTIVE SUMMARY
49
PREMIUM INSIGHTS
54
MARKET OVERVIEW
58
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increased investments in precision medicines
    - Rising demand for generic drugs
    - Need for affordable drug development
    - Favorable initiatives by contract development and manufacturing organizations
    RESTRAINTS
    - Stringent regulatory requirements
    OPPORTUNITIES
    - Emergence of cell and gene therapies
    - Growing inclination toward one-stop-shop model
    - Growth opportunities in emerging countries
    - Booming nuclear medicine market
    CHALLENGES
    - Introduction of serialization
    - Intellectual property risk
  • 5.3 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS, BY SERVICE
    INDICATIVE PRICING ANALYSIS, BY REGION
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Single-use bioprocessing systems
    - Continuous manufacturing
    - Advanced formulation technologies
    COMPLEMENTARY TECHNOLOGIES
    - High-performance liquid chromatography
    - Mass spectrometry
    - Next-generation sequencing
    - Automation and robotics
    - Process analytical technology
    ADJACENT TECHNOLOGIES
    - 3D printing
    - Artificial intelligence and machine learning
  • 5.8 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.13 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
96
  • 6.1 INTRODUCTION
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    PHARMACEUTICAL API MANUFACTURING SERVICES
    - Rising cases of patent expiry to fuel market
    PHARMACEUTICAL FDF MANUFACTURING SERVICES
    - Parenteral manufacturing services
    - Tablet manufacturing services
    - Capsule manufacturing services
    - Oral liquid manufacturing services
    - Semi-solid manufacturing services
    - Other FDF manufacturing services
  • 6.3 DRUG DEVELOPMENT SERVICES
    INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    BIOLOGICS API MANUFACTURING SERVICES
    - Expanding offerings in cell line development and production to aid market growth
    BIOLOGICS FDF MANUFACTURING SERVICES
    - Growing importance due to therapeutic potential to encourage growth
  • 6.5 PACKAGING & LABELING SERVICES
    INCREASING STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR MARKET GROWTH
  • 6.6 FILL-FINISH SERVICES
    SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO DRIVE MARKET
  • 6.7 OTHER SERVICES
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
155
  • 7.1 INTRODUCTION
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    RISING PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO MARKET GROWTH
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    NEED TO SAVE COSTS ON IN-HOUSE DRUG MANUFACTURING TO BOOST MARKET
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
  • 7.5 OTHER END USERS
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
171
  • 8.1 INTRODUCTION
  • 8.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Presence of major pharmaceutical companies to drive market
    CANADA
    - Favorable government support to sustain market growth
  • 8.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Free drug pricing policy to speed up market growth
    UK
    - Favorable R&D funding scenario to augment growth
    FRANCE
    - Booming life science research to fuel market
    ITALY
    - Rising commercial drug development to favor growth
    SWITZERLAND
    - Role as global pharmaceutical manufacturing hub to fuel market
    POLAND
    - Universal health coverage and advanced infrastructure to encourage growth
    SPAIN
    - Growing outsourcing of development and trial phases to boost market
    REST OF EUROPE
  • 8.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Made in China 2025 initiative to aid market growth
    INDIA
    - Favorable industrial environment and lower labor costs to drive market
    AUSTRALIA
    - Strategic geographical location to foster growth
    JAPAN
    - Growing geriatric population to augment growth
    SOUTH KOREA
    - Initiatives for enhanced workforce, improved regulations, and R&D for new drugs to promote growth
    REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rapid patient enrolment and presence of highly experienced investigators for clinical trials to expedite growth
    MEXICO
    - Surge in pharmaceutical goods export to promote growth
    REST OF LATIN AMERICA
  • 8.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Kingdom of Saudi Arabia
    - UAE
    - Other GCC Countries
    REST OF MIDDLE EAST
  • 8.7 AFRICA
    RISING CASES OF CANCER AND OTHER CHRONIC DISEASES TO FACILITATE GROWTH
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
270
  • 9.1 INTRODUCTION
  • 9.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 9.3 REVENUE ANALYSIS
  • 9.4 MARKET SHARE ANALYSIS
  • 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Service footprint
    - End-user footprint
    - Region footprint
  • 9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 9.7 BRAND/SERVICE COMPARISON
    THERMO FISHER SCIENTIFIC INC.
    CATALENT, INC.
    LONZA
    SAMSUNG BIOLOGICS
    WUXI APPTEC
  • 9.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 9.9 COMPETITIVE SCENARIO
    SERVICE LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
294
  • 10.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    LONZA
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    CATALENT, INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI APPTEC
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    SAMSUNG BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Services offered
    - Recent developments
    EVONIK INDUSTRIES AG
    - Business overview
    - Services offered
    - Recent developments
    FUJIFILM HOLDINGS CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    ABBVIE INC.
    - Business overview
    - Services offered
    - Recent developments
    SIEGFRIED HOLDING AG
    - Business overview
    - Services offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Services offered
    - Recent developments
    ALMAC GROUP
    - Business overview
    - Services offered
    - Recent developments
    CHARLES RIVER LABORATORIES
    - Business overview
    - Services offered
    - Recent developments
    ASYMCHEM INC.
    - Business overview
    - Services offered
    - Recent developments
    VETTER PHARMA
    - Business overview
    - Services offered
    - Recent developments
    ALCAMI CORPORATION
    - Business overview
    - Services offered
    - Recent developments
  • 10.2 OTHER PLAYERS
    PIRAMAL PHARMA SOLUTIONS
    SYNGENE INTERNATIONAL LIMITED
    CAMBREX CORPORATION
    JUBILANT BIOSYS LTD.
    YUHAN CORPORATION
    PIERRE FABRE GROUP
    PFIZER CENTREONE
    DELPHARM
    FRONTAGE LABS
    SHARP SERVICES, LLC
    GRAND RIVER ASEPTIC MANUFACTURING
APPENDIX
376
  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 4 IMPENDING PATENT EXPIRY OF DRUGS, BY YEAR
  • TABLE 5 EXPANSIONS BY TOP COMPANIES, 2022–2024
  • TABLE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
  • TABLE 7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 9 REGULATORY SCENARIO, BY COUNTRY
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
  • TABLE 18 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING, BY END USER
  • TABLE 19 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 20 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 21 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 22 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 23 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 24 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 25 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 26 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 27 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 28 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 29 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 30 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 31 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 32 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 33 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 34 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 35 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 36 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 37 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 38 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 39 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 40 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 41 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 42 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 43 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 44 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 45 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 46 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 47 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 48 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 49 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 50 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 51 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 52 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 53 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 54 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 55 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 56 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 57 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 58 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 59 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 60 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 61 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 62 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 63 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 64 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 65 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 66 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 67 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 68 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 69 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 70 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 71 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 72 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 73 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 74 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 75 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 76 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 77 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 78 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 79 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 80 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 81 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 82 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 83 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 84 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 85 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 86 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 87 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 88 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 89 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 90 MIDDLE EAST: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 91 GCC COUNTRIES: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 92 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 93 BIOLOGICS MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 94 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 95 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 96 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 97 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 98 MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 99 GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 100 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 101 NORTH AMERICA: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 102 EUROPE: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 103 ASIA PACIFIC: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 104 LATIN AMERICA: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 105 MIDDLE EAST: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 106 GCC COUNTRIES: BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 107 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 108 NORTH AMERICA: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 109 EUROPE: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 110 ASIA PACIFIC: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 111 LATIN AMERICA: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 112 MIDDLE EAST: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 113 GCC COUNTRIES: BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 114 PACKAGING & LABELING SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 115 NORTH AMERICA: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 116 EUROPE: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 117 ASIA PACIFIC: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 118 LATIN AMERICA: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 119 MIDDLE EAST: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 120 GCC COUNTRIES: PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 121 FILL-FINISH SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 122 NORTH AMERICA: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 123 EUROPE: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 124 ASIA PACIFIC: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 125 LATIN AMERICA: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 126 MIDDLE EAST: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 127 GCC COUNTRIES: FILL-FINISH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 128 OTHER SERVICES MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 129 NORTH AMERICA: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 130 EUROPE: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 131 ASIA PACIFIC: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 132 LATIN AMERICA: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 133 MIDDLE EAST: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 134 GCC COUNTRIES: OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 135 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 136 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 137 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 138 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 139 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 140 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 141 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 142 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 143 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 144 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 145 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 146 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 147 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 148 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 149 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2022–2029 (USD BILLION)
  • TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 166 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 167 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 168 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 169 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 170 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 171 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 172 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 173 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 174 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 175 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 176 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 177 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 178 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 179 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 180 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 181 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 182 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 183 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 184 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 185 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 186 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 187 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 188 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 189 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 190 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 191 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 192 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 193 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 194 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 195 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 196 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 197 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 198 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 199 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 200 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 201 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 202 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 203 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 204 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 205 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 206 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 207 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 208 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 209 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 210 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 211 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 212 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 213 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 214 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 215 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 216 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 217 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 218 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 219 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 220 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 221 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 222 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 223 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 224 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 225 REST OF EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 226 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 227 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 228 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 229 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 230 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 231 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 232 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 233 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 234 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 235 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 236 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 237 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 238 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 239 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 240 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 241 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 242 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 243 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 244 AUSTRALIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 245 AUSTRALIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 246 AUSTRALIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 247 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 248 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 249 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 250 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 251 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 252 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 253 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 254 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 255 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 256 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 257 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 258 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 259 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 260 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 261 REST OF ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 262 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 263 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
  • TABLE 264 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 265 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 266 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 267 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 268 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 269 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 270 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 271 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 272 BRAZIL: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 273 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 274 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 275 MEXICO: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 276 MEXICO: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 277 MEXICO: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 278 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 279 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 280 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 281 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 282 REST OF LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 283 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 284 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 285 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 286 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 287 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 288 MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 289 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 290 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 291 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 292 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 293 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 294 GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 295 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 296 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 297 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 298 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 299 KINGDOM OF SAUDI ARABIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 300 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 301 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 302 UAE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 303 UAE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 304 UAE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 305 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 306 OTHER GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 307 OTHER GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 308 OTHER GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 309 OTHER GCC COUNTRIES: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 310 OTHER GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 311 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 312 REST OF MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 313 REST OF MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 314 REST OF MIDDLE EAST: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 315 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 316 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD BILLION)
  • TABLE 317 AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 318 AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 319 AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)
  • TABLE 320 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2022–2029 (USD BILLION)
  • TABLE 321 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • TABLE 322 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • TABLE 323 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE FOOTPRINT
  • TABLE 324 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: END-USER FOOTPRINT
  • TABLE 325 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
  • TABLE 326 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 327 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 328 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2021–JULY 2024
  • TABLE 329 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2021–JULY 2024
  • TABLE 330 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 331 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 332 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 333 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–JULY 2024
  • TABLE 334 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 335 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 336 LONZA: COMPANY OVERVIEW
  • TABLE 337 LONZA: SERVICES OFFERED
  • TABLE 338 LONZA: DEALS, JANUARY 2021–JULY 2024
  • TABLE 339 LONZA: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 340 CATALENT, INC.: COMPANY OVERVIEW
  • TABLE 341 CATALENT, INC.: SERVICES OFFERED
  • TABLE 342 CATALENT, INC.: SERVICE LAUNCHES, JANUARY 2021–JULY 2024
  • TABLE 343 CATALENT, INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 344 CATALENT, INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 345 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 346 WUXI APPTEC: SERVICES OFFERED
  • TABLE 347 WUXI APPTEC: DEALS, JANUARY 2021–JULY 2024
  • TABLE 348 WUXI APPTEC: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 349 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 350 WUXI BIOLOGICS: SERVICES OFFERED
  • TABLE 351 WUXI BIOLOGICS: DEALS, JANUARY 2021–JULY 2024
  • TABLE 352 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 353 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
  • TABLE 354 SAMSUNG BIOLOGICS: SERVICES OFFERED
  • TABLE 355 SAMSUNG BIOLOGICS: DEALS, JANUARY 2021–JULY 2024
  • TABLE 356 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 357 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 358 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
  • TABLE 359 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–JULY 2024
  • TABLE 360 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 361 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
  • TABLE 362 EVONIK INDUSTRIES AG: SERVICES OFFERED
  • TABLE 363 EVONIK INDUSTRIES AG: DEALS, JANUARY 2021–JULY 2024
  • TABLE 364 EVONIK INDUSTRIES AG: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 365 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 366 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
  • TABLE 367 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021–JULY 2024
  • TABLE 368 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 369 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 370 ABBVIE INC.: SERVICES OFFERED
  • TABLE 371 ABBVIE INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 372 ABBVIE INC.: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 373 SIEGFRIED HOLDING AG: COMPANY OVERVIEW
  • TABLE 374 SIEGFRIED HOLDING AG: SERVICES OFFERED
  • TABLE 375 SIEGFRIED HOLDING AG: DEALS, JANUARY 2021–JULY 2024
  • TABLE 376 SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 377 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 378 MERCK KGAA: SERVICES OFFERED
  • TABLE 379 MERCK KGAA: DEALS, JANUARY 2021–JUNE 2024
  • TABLE 380 MERCK KGAA: EXPANSIONS, JANUARY 2021–JUNE 2024
  • TABLE 381 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 382 ALMAC GROUP: SERVICES OFFERED
  • TABLE 383 ALMAC GROUP: DEALS, JANUARY 2021–JULY 2024
  • TABLE 384 ALMAC GROUP: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 385 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 386 CHARLES RIVER LABORATORIES: SERVICES OFFERED
  • TABLE 387 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JULY 2024
  • TABLE 388 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 389 ASYMCHEM INC.: COMPANY OVERVIEW
  • TABLE 390 ASYMCHEM INC.: SERVICES OFFERED
  • TABLE 391 ASYMCHEM INC.: DEALS, JANUARY 2021–JUNE 2024
  • TABLE 392 ASYMCHEM INC.: EXPANSIONS, JANUARY 2021–JUNE 2024
  • TABLE 393 VETTER PHARMA: COMPANY OVERVIEW
  • TABLE 394 VETTER PHARMA: SERVICES OFFERED
  • TABLE 395 VETTER PHARMA: DEALS, JANUARY 2021–JULY 2024
  • TABLE 396 VETTER PHARMA: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 397 ALCAMI CORPORATION: COMPANY OVERVIEW
  • TABLE 398 ALCAMI CORPORATION: SERVICES OFFERED
  • TABLE 399 ALCAMI CORPORATION: DEALS, JANUARY 2021–JULY 2024
  • TABLE 400 ALCAMI CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2024
  • TABLE 401 PIRAMAL PHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 402 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 403 CAMBREX CORPORATION: COMPANY OVERVIEW
  • TABLE 404 JUBILANT BIOSYS LTD.: COMPANY OVERVIEW
  • TABLE 405 YUHAN CORPORATION: COMPANY OVERVIEW
  • TABLE 406 PIERRE FABRE GROUP: COMPANY OVERVIEW
  • TABLE 407 PFIZER CENTREONE: COMPANY OVERVIEW
  • TABLE 408 DELPHARM: COMPANY OVERVIEW
  • TABLE 409 FRONTAGE LABS: COMPANY OVERVIEW
  • TABLE 410 SHARP SERVICES, LLC: COMPANY OVERVIEW
  • TABLE 411 GRAND RIVER ASEPTIC MANUFACTURING: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS, 2024–2029
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 13 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
  • FIGURE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
  • FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2024–2029
  • FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
  • FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 20 CHINA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 21 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 AVERAGE COST OF DEVELOPING COMPOUNDS FOR BIOPHARMA COMPANIES, 2013–2023 (USD BILLION)
  • FIGURE 23 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
  • FIGURE 28 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 29 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 30 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2019–2023
  • FIGURE 31 REGIONAL BREAKDOWN OF ANDA (ABBREVIATED NEW DRUG APPLICATION) APPROVALS IN 2023
  • FIGURE 32 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS FOR DOSAGE FORMS IN 2023
  • FIGURE 33 INVESTMENT AND FUNDING SCENARIO (2023–2024)
  • FIGURE 34 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • FIGURE 35 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2019–2023 (USD BILLION)
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY PLAYER, 2023
  • FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
  • FIGURE 41 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 LONZA: COMPANY SNAPSHOT (2023)
  • FIGURE 47 CATALENT, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 WUXI APPTEC: COMPANY SNAPSHOT (2023)
  • FIGURE 49 WUXI BIOLOGICS: COMPANY SNAPSHOT (2023)
  • FIGURE 50 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2023)
  • FIGURE 51 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)
  • FIGURE 52 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023)
  • FIGURE 53 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 54 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2023)
  • FIGURE 56 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 57 ASYMCHEM INC.: COMPANY SNAPSHOT (2023)

This research study extensively utilized secondary sources, directories, and databases to discover and gather relevant information for the examination of the worldwide pharmaceutical contract manufacturing. Extensive interviews were carried out with primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of major market players, and industry consultants. The purpose was to gather and confirm essential qualitative and quantitative information, as well as evaluate the market's potential for growth. The final market size was determined by triangulating the worldwide market size estimated from secondary research with inputs from primary research.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract manufacturing market. The secondary sources used for this study include Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Pharma Times, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information, Eurostat, Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC),  Pharmaceutical Research and Manufacturers of America (PhRMA), World Journal of Pharmaceutical Sciences, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global pharmaceutical contract manufacturing market scenario through secondary research. Market experts from the demand side—big pharmaceutical companies, small and medium-sized pharmaceutical companies, generic pharmaceutical companies, CROs, C-level and D-level executives, product managers, marketing and sales managers of major manufacturers, distributors, and channel partners—as well as experts from the supply side—C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners. Six main areas—Asia Pacific, North America, Europe, Latin America, Middle East, and Africa—were the sites of these interviews. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand side participants, respectively. Questionnaires, emails, web surveys, personal interviews, and phone calls gathered this main data.

The following is a breakdown of the primary respondents:

Pharmaceutical  Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the pharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the pharmaceutical contract manufacturing business of leading players have been determined through primary and secondary research to arrive at the overall pharmaceutical contract manufacturing market.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
  • Additionally, to arrive at the pharmaceutical contract manufacturing market for each service, the pharmaceutical contract manufacturing business shares of leading players for each service category were also gathered from secondary sources to the extent available. In some instances, the shares of pharmaceutical contract manufacturing businesses were ascertained through a detailed analysis of various parameters, including service portfolios and market positioning.
  • Individual shares or revenue estimates were validated through expert interviews.

Pharmaceutical  Contract Manufacturing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Pharmaceutical  Contract Manufacturing Market Size, and Share

Data Triangulation

After arriving at the market size  from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmaceutical contract manufacturing organizations (CMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CMOs offer manufacturing services for active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Different aspects of contract manufacturing, such as drug development & manufacturing, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this report.

Stakeholders

  • Corporate Entities
  • Venture Capitalists
  • Regulatory Agencies
  • Government Agencies
  • Private Research Firms
  • Academic and Research Institutions
  • Pharmaceutical Distributors and Suppliers
  • Biotechnology and Pharmaceutical Companies
  • Business Research and Consulting Service Providers
  • Contract Research Organizations and Contract Development Manufacturing Organizations

Report Objectives

  • To define, describe, and forecast the global pharmaceutical contract manufacturing market based on the service, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical contract manufacturing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the pharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments in the pharmaceutical contract manufacturing market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
  • To benchmark players within the pharmaceutical contract manufacturing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

1 Micro markets are the further segments and subsegments of the pharmaceutical contract manufacturing market included in the report

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific pharmaceutical contract manufacturing market into countries
  • A further breakdown of the Rest of European pharmaceutical contract manufacturing market into countries
  • A further breakdown of the Rest of Latin American pharmaceutical contract manufacturing market into countries
  • A further breakdown of the Rest of Middle East pharmaceutical contract manufacturing market into countries

Previous Versions of this Report

Pharmaceutical Contract Manufacturing Market By Services (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) & Region - Global Forecast to 2026

Report Code PH 7263
Published in Apr, 2023, By MarketsandMarkets™

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma, CRO)-Global Forecast to 2026

Report Code PH 7263
Published in Oct, 2021, By MarketsandMarkets™

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025

Report Code PH 7263
Published in Mar, 2021, By MarketsandMarkets™

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025

Report Code PH 7263
Published in Jul, 2019, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Pharmaceutical Contract Manufacturing Market

Kahlill

Feb, 2023

What will be the key challenges for business in the pharmaceutical contract manufacturing market in the near future?.

James

Jul, 2023

Key players in pharmaceutical contract manufacturing industry for North America region include:

  • Pfizer
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Roche
  • Novartis
  • GlaxoSmithKline
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company among others
.

James

Jul, 2023

Who are the top key players in the pharmaceutical contract manufacturing market in North America?.

DMCA.com Protection Status